https://www.selleckchem.com/pr....oducts/oss-128167.ht
Our results showed anlotinib alone or combined with cisplatin inhibited cell proliferation, migration, and invasion and activated apoptosis in colorectal cancer cells. Furthermore, we found that anlotinib inhibiting the phosphorylation level of VEGFR, Janus Kinase 2 (JAK2), and Signal Transducer and Activator of Transcription 3 (STAT3). Combination chemotherapy of anlotinib with cisplatin is more sensitive to colorectal cancer. These findings suggested that anlotinib might benefit colorectal cancer therapy by antagonizing VEGFR/JAK2/
Like
Comment
Share
